Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Elevation Oncology's EO-3021?
EO-3021 is a monoclonal antibody conjugated commercialized by Elevation Oncology, with a leading Phase I program in Metastatic Pancreatic Cancer....